AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 129 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $193,020,000 | +213.3% | 3,225,613 | +47.1% | 0.01% | +250.0% |
| Q3 2019 | $61,607,000 | -17.4% | 2,193,212 | +11.3% | 0.00% | -33.3% |
| Q2 2019 | $74,629,000 | +1.4% | 1,971,206 | +4.5% | 0.00% | 0.0% |
| Q1 2019 | $73,613,000 | +102.3% | 1,886,547 | +10.5% | 0.00% | +50.0% |
| Q4 2018 | $36,384,000 | -31.6% | 1,706,529 | +27.1% | 0.00% | 0.0% |
| Q3 2018 | $53,166,000 | +5.5% | 1,342,931 | +1.9% | 0.00% | 0.0% |
| Q2 2018 | $50,374,000 | +42.8% | 1,318,346 | +12.3% | 0.00% | 0.0% |
| Q1 2018 | $35,288,000 | +24.6% | 1,174,306 | +29.6% | 0.00% | +100.0% |
| Q4 2017 | $28,325,000 | +34.3% | 906,361 | +20.3% | 0.00% | 0.0% |
| Q3 2017 | $21,098,000 | +62.6% | 753,246 | +11.0% | 0.00% | 0.0% |
| Q2 2017 | $12,978,000 | +158.6% | 678,412 | +130.3% | 0.00% | – |
| Q1 2017 | $5,019,000 | +0.9% | 294,575 | +8.2% | 0.00% | – |
| Q4 2016 | $4,975,000 | +16.4% | 272,292 | +13.4% | 0.00% | – |
| Q3 2016 | $4,275,000 | – | 240,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |